FSTX · F-Star Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $21.17M | $11.26M | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $28.75M | $14.13M | $23.27M | $19.75M | $13.07M | $14.02M |
| SG&A | $23.13M | $19.51M | $9.75M | $8.72M | $8.18M | $5.74M |
| Total Operating Expenses | $51.88M | $33.64M | $33.02M | $28.47M | $21.25M | $19.76M |
| D&A | $562.0K | $1.14M | $357.0K | $288.0K | $158.0K | $118.0K |
| Operating Income | ($30.71M) | ($22.39M) | ($33.02M) | ($28.47M) | ($21.25M) | ($19.40M) |
| Interest Expense | $1.00M | - | $542.0K | - | - | - |
| Income Tax | ($372.0K) | ($1.0K) | $0 | $0 | $0 | $0 |
| Net Income | ($31.28M) | ($25.62M) | ($24.10M) | ($22.85M) | ($27.68M) | ($17.37M) |
| EPS - Basic | - | - | ($1.46) | ($2.48) | - | - |
| EPS - Diluted | - | - | ($1.46) | ($1.88) | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $78.55M | $18.53M | $28.71M | $14.72M | $23.65M | $10.68M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.08M | $4.60M | $2.21M | $1.88M | $1.70M | $1.52M |
| Current Assets | $84.74M | $26.07M | $57.98M | $49.29M | $51.13M | $25.57M |
| Total Assets | $123.02M | $63.61M | $63.20M | $68.81M | $52.34M | $26.88M |
| Current Liabilities | $12.13M | $16.98M | $5.41M | $4.25M | $4.43M | $3.50M |
| Long-term Debt | $9.61M | - | $19.07M | - | - | - |
| Total Liabilities | $26.16M | $20.61M | $27.67M | $12.95M | $17.59M | $3.55M |
| Stockholders' Equity | $96.86M | $42.99M | $35.53M | $55.86M | $34.75M | $12.20M |
| Retained Earnings | ($78.45M) | ($47.17M) | ($126.17M) | ($102.07M) | ($79.21M) | ($51.53M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($27.27M) | ($16.23M) | ($29.05M) | ($17.68M) | ($17.68M) | ($15.85M) |
| Investing Cash Flow | ($643.0K) | $14.05M | $23.50M | ($12.41M) | ($12.41M) | ($6.48M) |
| Financing Cash Flow | $88.10M | $15.85M | $19.54M | $41.17M | $43.54M | $28.66M |
| CapEx | $658.0K | - | $272.0K | $1.97M | $323.0K | $213.0K |
| Free Cash Flow | ($27.93M) | - | ($29.33M) | ($19.66M) | ($18.01M) | ($16.06M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -145.1% | -198.9% | - | - | - | - |
| EBITDA margin | -142.4% | -188.7% | - | - | - | - |
| Net margin | -147.8% | -227.6% | - | - | - | - |
| Free cash flow margin | -131.9% | - | - | - | - | - |
| FCF / Net income | 0.89 | - | 1.22 | 0.86 | 0.65 | 0.92 |
| R&D / Revenue | 135.8% | 125.5% | - | - | - | - |
| SG&A / Revenue | 109.3% | 173.4% | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -25.4% | -40.3% | -38.1% | -33.2% | -52.9% | -64.6% |
| Return on equity | -32.3% | -59.6% | -67.8% | -40.9% | -79.7% | -142.3% |
| Return on invested capital | -22.8% | - | -47.8% | - | - | - |
| Liquidity | ||||||
| Current ratio | 6.98 | 1.54 | 10.72 | 11.61 | 11.53 | 7.30 |
| Quick ratio | 6.98 | 1.54 | 10.72 | 11.61 | 11.53 | 7.30 |
| Cash ratio | 6.47 | 1.09 | 5.31 | 3.47 | 5.33 | 3.05 |
| Leverage | ||||||
| Debt / Equity | 0.10 | - | 0.54 | - | - | - |
| Debt / Assets | 0.08 | - | 0.30 | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -30.7x | - | -60.9x | - | - | - |
| Equity multiplier | 1.27 | 1.48 | 1.78 | 1.23 | 1.51 | 2.20 |
| Liabilities / Assets | 0.21 | 0.32 | 0.44 | 0.19 | 0.34 | 0.13 |
| Efficiency | ||||||
| Asset turnover | 0.17 | 0.18 | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 88.1% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -37.2% | 32.2% | -16.0% | -34.0% | -9.5% | - |
| Net income growth (YoY) | -22.1% | -6.3% | -5.4% | 17.4% | -59.4% | - |
| EPS growth (YoY) | - | - | 22.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -49.2% | -9.2% | -12.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 125.3% | 21.0% | -36.4% | 60.8% | 184.8% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Geographic
$18.25M totalUS$17.50M · 95.9%
SE$500.0K · 2.7%
Other$250.0K · 1.4%
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
0.83
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing F-star Therapeutics against the 5 most active filers in the same SIC group.